Zika Virus Vaccine
Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
1 - 17 . (canceled)
18 . A Zika virus vaccine comprising a Zika virus having an RNA genome corresponding to the DNA sequence provided by any one of SEQ ID NOs: 2-13 or 72 or a variant nucleic acid having at least 99% identity to any one of SEQ ID NOs: 2-13 or 72 and able to pack a virulent Zika virus, wherein the sequence identity is determined by Needleman-Wunsch homology alignment.
19 . The Zika virus vaccine according to claim 18 , wherein the variant nucleic acid has at least 99.5% identity to any one of SEQ ID NOs: 2-13 or 72.
20 . The Zika virus vaccine according to claim 18 , wherein the variant nucleic acid has at least 99.6% identity to any one of SEQ ID NOs: 2-13 or 72.
21 . The Zika virus vaccine according to claim 18 , wherein the variant nucleic acid has at least 99.7% identity to any one of SEQ ID NOs: 2-13 or 72.
22 . The Zika virus vaccine according to claim 18 , wherein the variant nucleic acid has at least 99.8% identity to any one of SEQ ID NOs: 2-13 or 72.
23 . The Zika virus vaccine according to claim 18 , wherein the variant nucleic acid has at least 99.9% identity to any one of SEQ ID NOs: 2-13 or 72.
24 . The Zika virus vaccine according to claim 18 , wherein said Zika virus vaccine is capable of stimulating a neutralizing antibody titer greater than 15 in at least 70% of vaccinated subjects, wherein the neutralizing antibody titer is determined using a microneutralization assay (MN50) following a single administration of the Zika virus vaccine to a subject.
25 . The Zika virus vaccine according to claim 18 , wherein the Zika virus comprises an E protein having an amino acid sequence provided by any one of SEQ ID NOs: 24, 27, 35, 36, 40, 42, 47, 49, 53 or 66.
26 . The Zika virus vaccine of claim 24 , wherein the Zika virus vaccine is capable of stimulating a MN 50 titer greater than 15 in at least 80% of vaccinated subjects.
27 . The Zika virus vaccine of claim 24 , wherein the Zika virus vaccine is capable of stimulating a MN 50 titer greater than 15 in at least 90% of vaccinated subjects.
28 . The Zika virus vaccine of claim 24 , wherein the Zika virus vaccine is capable of stimulating a MN 50 titer greater than 15 in at least 95% of vaccinated subjects.
29 . The Zika virus vaccine of claim 24 , wherein the Zika virus vaccine is capable of stimulating a MN 50 titer greater than 15 in at least 99% of vaccinated subjects.
30 . The Zika virus vaccine of claim 18 , wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.
31 . The Zika virus vaccine of claim 18 , further comprising an adjuvant.
32 . The Zika virus vaccine of claim 31 , wherein the adjuvant is an aluminium salt adjuvant.
33 . The Zika virus vaccine of claim 32 , wherein said aluminium salt adjuvant is aluminium hydroxide with less than 1.25 parts per billion copper based on a final pharmaceutical composition comprising the Zika virus.
34 . The Zika virus vaccine of claim 18 , wherein the vaccine comprises protamine sulphate (PS) or fragments or break-down products of PS at amounts below the limits of detection by high performance liquid chromatography (HPLC).
35 . The Zika virus vaccine of claim 34 , wherein the vaccine comprises protamine sulphate (PS) or fragments or break-down products of PS at amounts below 1 μg/mL or below 100 ng/mL.
36 . The Zika virus vaccine of claim 34 , wherein said PS or fragments or break-down products of PS are detectable by mass spectroscopy.
37 . The Zika virus vaccine of claim 31 , further comprising a TLR9 agonist.